Biotinylated Human CEACAM-5/CD66e Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00264P-100UG
Biotinylated Human CEACAM-5 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human CEACAM-5/CD66e Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00264P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human CEACAM-5/CD66e Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus.It contains Lys35-Ala685. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P06731 |
Target Symbol | CEACAM-5/CD66e |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Lys35-Ala685 |
Mol. Weight | The protein has a predicted MW of 74.23 kDa. Due to glycosylation, the protein migrates to 110-150 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 20mM PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Biotinylated Human CEACAM-5, His Tag at 2ug/ml (100ul/well) on the streptavidin precoated plate (5ug/ml). Dose response curve for Anti-CEACAM Antibody, hFc Tag with the EC50 of 10.4ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified as a metastatic driver. CEACAM5 overproduction enriched for an epithelial gene expression pattern and facilitated tumor outgrowth at metastatic sites. Tissues from patients with metastatic breast cancer confirmed elevated levels of CEACAM5 in lung metastases relative to breast tumors, and an inverse correlation between CEACAM5 and the mesenchymal marker vimentin was demonstrated. |